On-demand PPI therapy in GERD

Current Treatment Options in Gastroenterology

Volumn 11, Issue 1, 2008, Pages 35-42

  Pace, Fabio ^a   Porro, Gabriele Bianchi ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; BENZODIAZEPINE DERIVATIVE; BICARBONATE; DIGOXIN; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; ITRACONAZOLE; KETOCONAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PHENYTOIN; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; STOMACH SECRETION INHIBITOR; WARFARIN;

ABDOMINAL PAIN; ARTHRALGIA; BARRETT ESOPHAGUS; BLURRED VISION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE CONTROL; DISEASE SEVERITY; DIZZINESS; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECONOMIC ASPECT; ENDOSCOPY; ESOPHAGITIS; ESOPHAGUS STRICTURE; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; HUMAN; HYPERGASTRINEMIA; HYPERSENSITIVITY REACTION; INTERSTITIAL NEPHRITIS; LIFESTYLE MODIFICATION; LIVER FUNCTION TEST; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; MYALGIA; PREVALENCE; QUALITY OF LIFE; REFLUX ESOPHAGITIS; REVIEW; SHORT COURSE THERAPY; SIDE EFFECT; STOMACH ACID SECRETION;

EID: 58649103295     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-008-0005-y     Document Type: Review

References (28)

1. Dent J, El-Serag HB, Wallander MA, Johansson S: Epidemiology of gastroesophageal reflux disease: A systematic review. Gut 2005, 54: 710-717.
2. Lagergren J, Bergstrom R, Lindgren A, Nyren O: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999, 340: 825-831.
3. Kulig M, Leodolter A, Vieth M, et al.: Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease-an analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003, 18: 767-776.
4. Agreus L, Borgquist L: The cost of gastro-oesophageal reflux disease, dyspepsia and peptic ulcer disease in Sweden. Pharmacoeconomics 2002, 20: 347-355.
5. Willich SN, Nocon M, Kulig M, et al.: Cost-of-disease analysis in patients with gastro-oesophageal reflux disease and Barrett's mucosa. Aliment Pharmacol Ther 2006, 23: 371-376.
6. Hampel H,OAbraham NS, El-Serag HB: Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005, 143: 199-211.
7. Kaltenbach T, Crockett S, Gerson LB: Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006, 166: 965-971.
8. Moayyedi P, Talley N: Gastroesophageal reflux disease. Lancet 2006, 367: 2086-2100.
9. Donnellan C, Sharma N, Preston C, Moayyedi P: Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005, 2: CD003245.
10. Zacny J, ZamaThshary M, Sketris I, Van Zanten V: Systematic review: the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005, 21: 1299-1312.
11. Pace F, ToninM M, Pallotta S, et al.: Systematic review: maintenance treatment of gastroesophageal reflux disease with proton pump inhibitors taken "on-demand." Aliment Pharmacol Ther 2007, 26: 195-204.
12. DeVault KR, Castell DO: Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2006, 100: 190-200.
13. Lind T, Havelund T, Lundell L, et al.: On-demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis-a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999, 13: 907-914.
14. Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al.: Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: A controlled trial of 'on-demand' therapy for 6 months. Aliment Pharmacol Ther 2001, 15: 347-354.
15. Talley NJ, Venables TL, Green JR, et al.: Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: A placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002, 14: 857-863.
16. Bytzer P, Blum A, De Herdt D, et al.: Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with nonerosive reflux disease. Aliment Pharmacol Ther 2004, 20: 181-188.
17. Scholten T, Dekkers CP, Schutze K, et al.: On-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD: The ORION trial. Digestion 2005, 72: 76-85.
18. Kaspari S, Kupcinskas L, Heinze H, Berghofer P: Pantoprazole 20 mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2005, 17: 935-941.
19. Bigard MA, Genestin E: Treatment of patients with heart-burn without endoscopic evaluation: On-demand treatment after effective continuous administration of lansoprazole 15 mg. Aliment Pharmacol Ther 2005, 22: 635-643.
20. Bour B, Staub JL, Chousterman M, et al.: Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: 'on-demand' treatment compared with continuous treatment. Aliment Pharmacol Ther 2005, 21: 805-812.
21. Sjöstedt S, Befrits R, Sylvan A, et al.: Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 2005, 22: 183-191.
22. Hansen N, Bergheim R, Fagertun H, et al.: A randomised prospective study comparing the effectiveness of esomeprazole treatment strategies in clinical practice for 6 months in the management of patients with symptoms of gastroesophageal reflux disease. Int J Clin Pract 2005, 59: 665-671.
23. Tsai HH, Chapman R, Shepherd A, et al.: Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: The COMMAND study. Aliment Pharmacol Ther 2004, 15: 657-665.
24. Hansen AN, Wahlqvist P, Jorgensen E, et al.: Six-month management of patients following treatment for gastroesophageal reflux disease symptoms-a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical practitioners setting. Int J Clin Pract 2005, 59: 655-664.
25. Labenz J, Petersen KU, Rosch W, Kolez HR: A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther 2003, 17: 1015-1019.
26. Dial S, Delaney JA, Barkun AN, Suissa S: Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005, 294: 2989-2995.
27. Laheij RJ, Sturkenboom MC, Hassing RJ, et al.: Risk of community-acquired pneumonia and use of gastric acid-suppressive agents. JAMA 2004, 292: 1955-1960.
28. Pace F, Manes G, Conio M, Bianchi Porro G: Pretreatment endoscopy - pro & contra: Endoscopy is needed before treatment in all patients with gastroesophageal reflux disease. Endoscopy 2006, 38: 271-275.